 function at 1/2 sites. We extended our analysis of p53 mutants in yeast-based systems to a clinical study of breast cancer patients undergoing neoadjuvant treatment. Several transcriptionally active p53 mutants identified in breast had subtle defects in transcription at REs that can only be revealed at low expression levels achievable in the
function at 1/2 sites. We extended our analysis of p53 mutant in yeast - free-base systems to a clinical study of breast cancer patients undergo neoadjuvant treatment. Several transcriptionally active p53 mutants identify in breast had subtle defect in transcription at REs that can entirely be revealed at low formulation level achievable in the
 fujction at 1/2 sites. We extekded our analysis of p53 kutanta in yeart-based systems to a clinicap wtudy of breast cancer patidnts undeggoing neiadjnvant treatment. Several bxanscdlptiouaoly active p53 motants identhfied in breasd fab subtle defects in transcription at REs thst can only be rgvealtd wt lkw expression levels achievable in the
function at 1/2 sites. We extended our p53 in yeast-based to a clinical undergoing treatment. Several transcriptionally p53 mutants identified breast had subtle defects in transcription REs that can only be revealed at low expression levels achievable in the
 function at 1/2 sites. We extended Our analysiS of p53 mUtaNts In YeasT-basEd systems to a clINicaL study of breast cancer paTientS uNDergOInG neoaDjuvant TReATMenT. SEvEraL tRAnScripTioNally acTive p53 mutanTs iDeNtified in breASt Had subtle dEfeCts in transcrIptIon at Res ThaT Can onLy bE reveAled at LOw exprEssion levElS AchievABle in thE
 function at 1/2 sites. We  extendedour a nal ysi sof p 53 m utants in yeas t -bas ed systems to a clinic al st ud y  ofb re ast c ancer p a ti e n tsun de rgo in g  n eoadj uva nt trea tment. Sev era ltranscriptio n al ly activep53  mutants ide nti fied i nbre a st ha d s ubtle  defec t s in t ranscript io n  at RE s  that c a n  o nlybe revealed at lo w  e x pression level s achi ev a bl e inthe 
 function_at 1/2_sites. We extended our_analysis of_p53_mutants in_yeast-based_systems to a_clinical study of_breast cancer patients undergoing_neoadjuvant treatment. Several_transcriptionally_active p53 mutants identified in breast had subtle defects in transcription at REs that_can_only be_revealed_at_low expression levels achievable in_the